Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galectin Therapeutics Inc GALT

Healthcare Biotechnology
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based... see more

Recent & Breaking News (NDAQ:GALT)

Research Reports Initiation on Generic Drugs Stocks -- Galectin Therapeutics, Momenta Pharma, Karyopharm Therapeutics, and Eagle Pharma

PR Newswire December 12, 2016

Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders

GlobeNewswire December 8, 2016

Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases

GlobeNewswire November 10, 2016

Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire November 8, 2016

Research Reports Coverage on Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine Biosciences, and Galectin Therapeutics

PR Newswire October 31, 2016

Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia

GlobeNewswire October 17, 2016

Galectin Therapeutics, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia

Accesswire October 11, 2016

Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis

GlobeNewswire October 7, 2016

12 Biggest Mid-Day Losers For Wednesday

Benzinga.com  October 5, 2016

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  September 29, 2016

Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX

Benzinga.com  September 29, 2016

Mid-Afternoon Market Update: Dow Gains 80 Points; Crude Oil Up 5%

Benzinga.com  September 28, 2016

Mid-Day Market Update: U.S. Stocks Turn Lower; Anavex Shares Spike Higher

Benzinga.com  September 28, 2016

Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Estimates

Benzinga.com  September 28, 2016

18 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  September 28, 2016

Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis

GlobeNewswire September 27, 2016

Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

GlobeNewswire August 31, 2016

Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

GlobeNewswire August 25, 2016

Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire August 9, 2016

Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

GlobeNewswire August 2, 2016